Jul 7, 2020

WeirFoulds represents StageZero Life Sciences Ltd. in $4.6M public offering

On June 29, 2020, StageZero Life Sciences Ltd. (“StageZero”) (TSX: SZLS) completed a public offering of 66,176,100 units (the “Units”) at a price of $0.07 per Unit raising aggregate gross proceeds of $4,632,327 (the “Offering”). Each Unit was comprised of one common share and one common share purchase warrant. The Units were offered by short form prospectus.

StageZero was represented by WeirFoulds LLP, with a team consisting of Rob Eberschlag, Conor Dooley, Ryan Morris, Alvin Yau, and Ann Lattanzio.

The net proceeds of the Offering will be used to fund StageZero’s expansion of COVID-19 testing capabilities, cancer testing product development, and other general corporate purposes. StageZero provides tests for the early detection of multiple diseases through whole blood testing. StageZero operates a CAP-accredited and CLIA-certified high complexity reference laboratory based in Richmond, Virginia providing both COVID-19 PCR testing (nasal swab) and blood test analysis (antibody testing).

WeirFoulds is pleased to have assisted StageZero in this public offering.

To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our securities practice group overview page.